SLC5A2 and type 2 diabetes mellitus: Cohort studies have identified increased amputation risk with canagliflozin,16 whilst studies of other SGLT2 inhibitors (empagliflozin, dapagliflozin and ertugliflozin) have demonstrated no increased LEA risk when compared to placebo in those with type 2 diabetes.10, 17, 18